Top

Published in:

01-06-2008 | Laboratory Research

Increased Expression of Fractalkine is Correlated with a Better Prognosis and an Increased Number of Both CD8⁺ T Cells and Natural Killer Cells in Gastric Adenocarcinoma

Authors: Miki Hyakudomi, MD, Takeshi Matsubara, MD, Ryoji Hyakudomi, MD, Tetsu Yamamoto, MD, Shoichi Kinugasa, MD, Akira Yamanoi, MD, Riruke Maruyama, MD, Tsuneo Tanaka, MD

Published in: Annals of Surgical Oncology | Issue 6/2008

Abstract

Background

Fractalkine (CX3CL1) is the only CX3C chemokine that can chemoattract natural killer (NK) cells, CD8⁺ T cells, monocytes, and dendritic cells. Although experimental studies have demonstrated that Fractalkine expression by tumor cells is related to the infiltrating lymphocytes and initiates antitumor immunity, the clinical significance of Fractalkine remains to be elucidated in gastric adenocarcinoma.

Methods

Tissue sections from 158 patients with curatively resected T2 or T3 gastric adenocarcinoma were immunohistochemically stained for Fractalkine. Furthermore, to evaluate CD8⁺ T cells and NK cells infiltration, antibodies to CD8 and CD57 protein were respectively used for immunohistochemistry.

Results

A significant direct correlation was observed between the Fractalkine scores and the number of CD8⁺ T cells and NK cells using the Spearman rank correlation coefficient test (P = .0080, .0031, respectively). Furthermore, the high Fractalkine expression group (n = 67) showed a significantly better prognosis than the low Fractalkine expression group (n = 91) regarding the disease-free survival (P = .0016). In a multivariate analysis, the Fractalkine expression was identified as one of the independent prognosticators for disease-free survival (risk ratio, 2.5; P = .0147).

Conclusions

These data suggest that the expression of Fractalkine by tumor cells enhances the recruitment of CD8⁺ T cells and NK cells and induces both innate and adaptive immunity, thereby yielding a better prognosis in gastric adenocarcinoma. Fractalkine is a new independent predictor of the prognosis and can be a novel candidate for development of a more effective therapeutic strategy for gastric adenocarcinomas.

Ono SJ, Nakamura T, Miyazaki D, et al. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003;111:1185–99PubMedCrossRef

Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1–8PubMed

Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50–6PubMedCrossRef

Guo J, Wang B, Zhang M, et al. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002;9:793–803PubMedCrossRef

Fushimi T, Kojima A, Moore MA, et al. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000;105:1383–93PubMedCrossRef

Dunussi-Joannopoulos K, Zuberek K, Runyon K, et al. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 2002;100:1551–8PubMed

Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–7PubMedCrossRef

Moser B, Wolf M, Walz A, et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25:75–84PubMedCrossRef

Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640–4PubMedCrossRef

10.

Matloubian M, David A, Engel S, et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000;1:298–304PubMedCrossRef

11.

Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413–9PubMedCrossRef

12.

Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521–30PubMedCrossRef

13.

Garton KJ, Gough PJ, Blobel CP, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001;276:37993–8001PubMed

14.

Hundhausen C, Misztela D, Berkhout TA, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003;102:1186–95PubMedCrossRef

15.

Nishimura M, Umehara H, Nakayama T, et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002;168:6173–80PubMed

16.

Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000;20:4106–14PubMedCrossRef

17.

Guo J, Zhang M, Wang B, et al. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003;103:212–20PubMedCrossRef

18.

Guo J, Chen T, Wang B, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003;89:1–7PubMedCrossRef

19.

Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005;35:1371–80PubMedCrossRef

20.

Lavergne E, Combadiere B, Bonduelle O, et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003;63:7468–74PubMed

21.

Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005;26:41–7PubMed

22.

Hira E, Ono T, Dhar DK, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005;103:588–98PubMedCrossRef

23.

Shibakita M, Tachibana M, Dhar DK, et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999;5:2464–9PubMed

24.

Okamura T, Kodama Y, Kamegawa T, et al. Gastric carcinoma with lymphoid stroma: correlation to reactive hyperplasia in regional lymph nodes and prognosis. Jpn J Surg 1983;13:177–83PubMedCrossRef

25.

Songun I, van de Velde CJ, Hermans J, et al. Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br J Cancer 1996;74:1783–8PubMed

26.

Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437–59PubMedCrossRef

27.

Usubutun A, Ayhan A, Uygur MC, et al. Prognostic factors in renal cell carcinoma. J Exp Clin Cancer Res 1998;17:77–81PubMed

28.

Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337–65PubMedCrossRef

29.

Pross HF, Lotzova E. Role of natural killer cells in cancer. Nat Immunol 1993;12:279–92

30.

Trinchieri G, Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab Invest 1984;50:489–513PubMed

31.

Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173–81PubMedCrossRef

32.

Rossi DL, Hardiman G, Copeland NG, et al. Cloning and characterization of a new type of mouse chemokine. Genomics 1998;47:163–70PubMedCrossRef

33.

Gao JQ, Tsuda Y, Katayama K, et al. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res 2003;63:4420–5PubMed

34.

Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000;88:577–83PubMedCrossRef

35.

Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9–14PubMedCrossRef

36.

Ishigami S, Natsugoe S, Tokuda K, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000;159:103–8PubMedCrossRef

37.

Maehara Y, Kabashima A, Tokunaga E, et al. Recurrences and relation to tumor growth potential and local immune response in node-negative advanced gastric cancer. Oncology 1999;56:322–7PubMedCrossRef

38.

Dichmann S, Herouy Y, Purlis D, Rheinen H, Gebicke-Harter P, Norgauer J. Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res 2001;50:529–33PubMedCrossRef

39.

Vitale S, Cambien B, Karimdjee BF, et al. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 2007;56:365–72PubMedCrossRef

Title: Increased Expression of Fractalkine is Correlated with a Better Prognosis and an Increased Number of Both CD8+ T Cells and Natural Killer Cells in Gastric Adenocarcinoma
Authors: Miki Hyakudomi, MD
Takeshi Matsubara, MD
Ryoji Hyakudomi, MD
Tetsu Yamamoto, MD
Shoichi Kinugasa, MD
Akira Yamanoi, MD
Riruke Maruyama, MD
Tsuneo Tanaka, MD
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-9876-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased Expression of Fractalkine is Correlated with a Better Prognosis and an Increased Number of Both CD8⁺ T Cells and Natural Killer Cells in Gastric Adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2008

Postoperative Mortality After Esophagectomy for Cancer: Development of a Preoperative Risk Prediction Model

Sentinel Nodes in Breast Cancer: Relevance of Axillary Level II Nodes and Optimal Number of Nodes that Need to Be Removed

Intraoperative Frozen Section Analysis of Sentinel Lymph Node in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Radiofrequency Ablation versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?

Surgical Complications and the Risk Factors of Laparoscopy-Assisted Distal Gastrectomy in Early Gastric Cancer

A Systematic Review of Radiofrequency Ablation for Lung Tumors